Eisai in Pact for Dementia-Drug Development
By

By
Eisai has formed a joint research agreement with Keio University, located in Tokyo, to discover and develop new drugs targeting dementia. For this collaborative research, a research lab will be…

Celgene in Antibody Drug Conjugate Pact
By

By
Celgene has formed a collaboration with Triphase Accelerator , a privately held drug development company headquartered in Toronto, under which Celgene has an option to acquire all Triphase Accelerator’s assets…

Biogen Board Approves Bioverativ Spin-Off
By

By
Biogen’s board of directors has approved the planned spin-off of its hemophilia business, Bioverativ Inc., and declared a special dividend distribution of all of the outstanding shares of Bioverativ common…

Astellas Completes Acquisition of Ganymed
By

By
Astellas Pharma has completed the acquisition of Ganymed Pharmaceuticals, a biopharmaceutical company located in Mainz, Germany. Ganymed has become a wholly owned subsidiary of Astellas as of December 20, 2016.…

Pfizer Completes Acquisition of AstraZeneca’s Anti-Infectives Biz
By

By
Pfizer has completed its previously announced acquisition of AstraZeneca’s late-stage small molecule anti-infective business. The agreement includes the commercialization and development rights primarily outside the US to the newly approved…

Baxter to Acquire Claris Injectables in $625-Million Deal
By

By
Baxter International has agreed to acquire Claris Injectables, a generic injectables pharmaceutical company based in Ahmedabad, India, for a total consideration of approximately $625 million. Claris Injectables is a wholly…

Lonza To Acquire Capsugel for $5.5 Billion
By

By
Lonza Group has agreed to acquire Capsugel from the private-equity firm KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion. With the proposed…

Monsanto Shareholders Approve $66 Billion Merger with Bayer
By

By
Bayer has cleared one hurdle in its proposed $66 billion acquisition of Monsanto, an agrochemical and seed company, with the shareholders of Monsanto approving the deal. The transaction is still…

Merck & Co., Sanofi Team with Natrix for Purification Tech
By

By
Merck & Co. and Sanofi have developed agreements with Natrix Separations, a Burlington, Ontario-based supplier of single-use and multi-cycle disposable chromatography products, to advance Natrix’s membrane-based Protein A technology platform…

Catalent Joins Pharmaceutical Supply Chain Initiative
By

By
Catalent Pharma Solutions has joined the Pharmaceutical Supply Chain Initiative (PSCI), a non-profit organization of pharmaceutical and healthcare companies designed to formalize, implement, and advocate responsible supply-chain practices. Catalent recently…